Washington, D.C. – A recent requirement implemented by the Federal Food and Drug Administration aims to provide women with more guidance regarding their breast density after a mammogram. Nearly 50% of women over the age of 40 have dense breast tissue, increasing their risk of developing cancer. However, many women are not informed about the implications of this diagnosis and what steps they should take next.
Breast density refers to the amount of glands and fibrous connective tissue in the breast, as opposed to fat. Research indicates that women with dense breasts are 4 to 5 times more likely to develop breast cancer compared to those without dense breasts. In addition to increasing the likelihood of developing tumors, dense breast tissue can make it challenging to detect abnormalities on mammogram images.
Advocates, such as Molly Guthrie from the Susan G. Komen Breast Cancer Foundation, have been pushing for breast density to be included on mammogram reports for the past decade. Previously, reports from some states provided limited or confusing information about breast density, leaving women uncertain about what it meant for their health.
The new FDA regulations aim to simplify the language used in mammogram reports to ensure that patients understand their breast density and associated risks. Patients will receive clearer guidance on whether additional imaging tests, such as ultrasounds or MRIs, may be necessary based on their breast density level.
Despite the requirement for regular mammograms to be covered by health plans without out-of-pocket costs, women requiring follow-up screenings may face additional expenses. Addressing out-of-pocket costs for these screenings is seen as the next crucial policy change needed to ensure that all women can access necessary breast cancer screenings.